# A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors

> **NCT00276913** · PHASE1 · COMPLETED · sponsor: **Synta Pharmaceuticals Corp.** · enrollment: 30 (—)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** STA-5312

## Key facts

- **NCT ID:** NCT00276913
- **Lead sponsor:** Synta Pharmaceuticals Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2014-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276913, "A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00276913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*